. 2020 May;36(3):223–232. doi: 10.6515/ACS.202005_36(3).20190920A

Table 2. Numbers of outcome events of the four groups categorized by baseline kidney function and post-PCI AKI status.

	Group 1 (n = 612)	Group 2 (n = 434)	Group 3 (n = 15)	Group 4 (n = 39)
90-day mortality (n, %)	12 (2.0%)*	14 (3.2%)^†	3 (20.0%)^‡	17 (43.6%)^§
ESRD (n, %)	1 (0.2%)	18 (4.1%)	0	4 (10.3%)^§
Long-term mortality (n, %)	63 (10.3%)^#	82 (18.9%)^†	4 (26.7%)	26 (66.7%)^§

Group 1: baseline eGFR ≥ 45 ml/min/1.73 m² and no AKI following PCI; Group 2: baseline eGFR < 45 ml/min/1.73 m² and no AKI following PCI; Group 3: baseline eGFR ≥ 45 ml/min/1.73 m² and developing AKI following PCI; Group 4: baseline eGFR < 45 ml/min/1.73 m² and developing AKI following PCI.

AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; PCI, percutaneous coronary intervention.

* Group 1 vs. 3, p value < 0.001. ^# Group 1 vs. 3, p value < 0.05. ^† Group 2 vs. 4, p value < 0.001. ^‡ Group 2 vs. 3, p value < 0.001. ^§ p value between 4 groups < 0.001.